Concord Medical Services (CCM) AI Stock Analysis

• Market Cap: $29.96M
• Dividend Yield: N/A
• Average Volume (3M): 46.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.15
• Revenue Growth: -29.82%
• EPS Growth: -2.57%
• Country: US
• Employees: 595
• Sector: Healthcare
• Sector Strength: 60
• Industry: Medical - Care Facilities
• EPS (TTM): -9.83
• Shares Outstanding: 2,815,458
• 10 Day Avg. Volume: 80,339
• 30 Day Avg. Volume: 46,371
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Concord Medical Services' stock faces significant challenges primarily due to its poor financial performance, characterized by declining revenue and high leverage. While technical indicators show some positive momentum, the company's negative P/E ratio and lack of dividends make it an unattractive investment for those seeking value or income. The absence of earnings call data or significant corporate events leaves the financial issues as the predominant factor impacting the stock score.

Concord Medical Services Business Overview & Revenue Model

Company Description

Concord Medical Services Holdings Limited (CCM) is a healthcare company that operates in the medical services sector, primarily focusing on providing specialty hospital management services and diagnostic imaging services. The company is based in China and is known for its extensive network of medical centers, which offer a wide range of services including radiotherapy, oncology, and diagnostic imaging. Concord Medical Services aims to enhance the quality of healthcare services in the regions it operates by leveraging advanced medical technologies and expertise.

How the Company Makes Money

Concord Medical Services generates revenue through several key streams. The primary source of income is from its network of medical centers, which offer diagnostic imaging services such as MRI, CT scans, and other advanced imaging technologies. Additionally, the company earns money through providing radiotherapy and oncology services. Concord Medical also engages in hospital management services, where it partners with hospitals to manage their radiotherapy and diagnostic imaging departments, sharing revenue from these operations. These strategic partnerships and the growing demand for specialized medical services in China contribute significantly to its earnings.

Concord Medical Services Financial Statement Overview

Summary

Concord Medical Services is facing significant financial difficulties with declining revenues, negative profit margins, heavily leveraged balance sheet, and negative cash flows. The company requires strategic restructuring or substantial capital infusion.

Income Statement

Concord Medical Services has experienced a persistent decline in revenue with a sharp drop from $537M in 2023 to $384M in 2024. Negative gross profit and EBIT margins indicate significant operational challenges. The net profit margin remains deeply negative, reflecting ongoing financial struggles.

Balance Sheet

The company's balance sheet shows considerable financial distress, with negative stockholders' equity reflecting a heavily leveraged position. The debt-to-equity ratio is not calculable due to negative equity, signaling high risk. Total liabilities exceed assets, indicating solvency issues.

Cash Flow

Cash flows are under pressure, with consistently negative operating and free cash flows. Despite a growth in financing cash flow, the reliance on external financing is unsustainable given the weak free cash flow to net income ratio, which remains negative.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
537.40M	472.08M	485.63M	223.01M	198.36M
	Gross Profit
-76.61M	-152.41M	-56.90M	13.08M	-15.83M
	EBIT
-462.99M	-525.05M	-458.32M	-316.00M	-437.29M
	EBITDA
-344.16M	-401.86M	-363.86M	-236.72M	-304.85M
	Net Income Common Stockholders
-297.66M	-489.66M	-271.43M	-309.99M	-307.05M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
58.14M	158.28M	157.39M	334.26M	74.31M
	Total Assets
6.05B	6.00B	6.23B	5.33B	4.30B
	Total Debt
3.30B	3.24B	2.73B	2.35B	1.85B
	Net Debt
3.24B	3.08B	2.58B	2.02B	1.78B
	Total Liabilities
4.31B	3.99B	3.49B	2.93B	2.41B
	Stockholders Equity
-2.12B	-1.86B	-1.37B	-662.96M	-122.76M
Cash Flow		Free Cash Flow
-392.17M	-600.47M	-1.12B	-734.47M	-896.27M
	Operating Cash Flow
-276.47M	-216.69M	-359.31M	-229.77M	-195.35M
	Investing Cash Flow
-47.68M	-118.79M	-565.98M	-533.88M	-1.07B
	Financing Cash Flow
257.65M	383.09M	642.45M	1.14B	513.27M

Concord Medical Services Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Positive. The current price of 6.75 is above the 20-day moving average (MA) of 5.33, above the 50-day MA of 4.83, and above the 200-day MA of 5.67, indicating a bullish trend. The MACD of 0.75 indicates Negative momentum. The RSI at 63.47 is Neutral, neither overbought nor oversold. The STOCH value of 44.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCM.

Concord Medical Services Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TOI	56 Neutral	$212.11M	―	-174.88%	―	21.33%	23.37%
AMS	53 Neutral	$18.01M	8.04	9.23%	―	32.90%	262.22%
Sector *	52 Neutral	$5.35B	3.83	-41.61%	2.85%	17.10%	1.22%
CCEL	49 Neutral	$39.20M	388.00	93.38%	10.25%	2.33%	―
PIII	42 Neutral	$63.20M	―	-124.59%	―	18.48%	-37.42%
MODV	34 Underperform	$20.94M	―	-341.96%	―	1.32%	1.95%
CCM	33 Underperform	$29.96M	―	14.03%	―	-29.82%	-2.57%